- Home
- EVRI vs ETNB Comparison
EVRI vs ETNB Comparison
Compare EVRI & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVRI
- ETNB
- Stock Information
- Founded
- EVRI 1998
- ETNB 2018
- Country
- EVRI United States
- ETNB United States
- Employees
- EVRI N/A
- ETNB N/A
- Industry
- EVRI Services-Misc. Amusement & Recreation
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- EVRI Consumer Discretionary
- ETNB Health Care
- Exchange
- EVRI Nasdaq
- ETNB Nasdaq
- Market Cap
- EVRI 1.2B
- ETNB 1.5B
- IPO Year
- EVRI 2005
- ETNB 2019
- Fundamental
- Price
- EVRI $14.22
- ETNB $10.08
- Analyst Decision
- EVRI Hold
- ETNB Strong Buy
- Analyst Count
- EVRI 4
- ETNB 8
- Target Price
- EVRI $12.83
- ETNB $26.43
- AVG Volume (30 Days)
- EVRI 1.4M
- ETNB 2.3M
- Earning Date
- EVRI 08-06-2025
- ETNB 08-04-2025
- Dividend Yield
- EVRI N/A
- ETNB N/A
- EPS Growth
- EVRI N/A
- ETNB N/A
- EPS
- EVRI 0.16
- ETNB N/A
- Revenue
- EVRI $749,853,000.00
- ETNB N/A
- Revenue This Year
- EVRI N/A
- ETNB N/A
- Revenue Next Year
- EVRI $2.19
- ETNB N/A
- P/E Ratio
- EVRI $88.88
- ETNB N/A
- Revenue Growth
- EVRI N/A
- ETNB N/A
- 52 Week Low
- EVRI $7.86
- ETNB $4.16
- 52 Week High
- EVRI $14.24
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- EVRI 70.72
- ETNB 57.88
- Support Level
- EVRI $14.13
- ETNB $9.66
- Resistance Level
- EVRI $14.24
- ETNB $10.58
- Average True Range (ATR)
- EVRI 0.04
- ETNB 0.55
- MACD
- EVRI -0.00
- ETNB -0.09
- Stochastic Oscillator
- EVRI 85.71
- ETNB 58.39
About EVRI Everi Holdings Inc.
Everi Holdings Inc provides entertainment and technology solutions for the casino, interactive, and gaming industry. It operates in two segments, namely Games and Financial Technology Solutions (FinTech). Enveri Games provides gaming operators with gaming technology products and services, which include gaming machines, slot machines, leased gaming equipment, and other products and services. Enveri FinTech provides gaming operators with financial technology products and services, which include services and equipment that facilitate casino patrons to access cash at gaming facilities through automated teller machines, point of sale debit card purchases, and others.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).